BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45
08 March 2023 - 8:01AM
On the eve of International Women’s Day
, BioSyent
Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the
Canadian launch of
FeraMAX®
Pd Maintenance 45 by its subsidiary, BioSyent
Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product
incorporating Polydextrose-Iron Complex (PDIC), a patented oral
iron supplement delivery system. The FeraMAX® Pd family of products
continues the innovation history of FeraMAX® and strengthens
BioSyent’s commitment to women’s health and the management of iron
health across various life stages. Iron deficiency
disproportionally affects women and children and is an independent
risk factor for decreased quality of life and increased morbidity
and mortality.i
“My personal approach to family medicine is
about prevention, with a focus on women’s health,” said Dr. Vivien
Brown, MDCM, CCFP, FCFP, NCMP, a busy family physician, tireless
women’s health advocate and preventative healthcare pioneer. “It is
important to recognize negative iron balance and managing those at
risk of iron deficiency, in advance of draining symptoms. I welcome
the addition of FeraMAX® Pd Maintenance 45 to my proactive approach
to iron health.”
FeraMAX® Pd Maintenance 45 is designed to
prevent iron deficiency, maintain healthy iron levels and to
address a gap in iron health therapy. This unique formulation
features 45 milligrams of elemental iron as Polydextrose-Iron
Complex (PDIC), along with 1,000 micrograms of vitamin B12 and 75
milligrams of vitamin C which supports the formation of red blood
cells and the immune system. FeraMAX® Pd Maintenance 45 is the only
iron supplement in Canada incorporating this unique supplement
combination in a convenient, orange-flavoured, chewable tablet -
taken once daily. FeraMAX® Pd Maintenance 45 is recognized by the
Society of Obstetricians and Gynaecologists of Canada. Made in a
Health Canada and FDA licensed facility, FeraMAX® Pd Maintenance 45
is vegan certified by Vegecert and is free of gluten, lactose, and
alcohol. FeraMAX® Pd Maintenance 45 is available in bottles of 30
chewable tablets, now commencing shipping to retail pharmacies
across Canada.
“BioSyent’s motivation for developing FeraMAX®
Pd Maintenance 45 is to help people who struggle with maintaining
iron sufficiency,” explained Mr. René C. Goehrum, President and CEO
of BioSyent. “Research with iron deficient patients indicates that
25% of those diagnosed with iron deficiency or iron deficiency
anemia have been previously diagnosed four times or more. Relapsing
iron deficiency is the impetus for this new addition. FeraMAX® Pd
Maintenance 45 is a result of BioSyent’s own innovation and product
development, to fill unmet medical needs and to improve the lives
of Canadians.”
FeraMAX® Pd Maintenance 45 joins the FeraMAX® Pd
family of oral iron products that includes FeraMAX® Pd Therapeutic
150 for the treatment of iron deficiency anemia, and FeraMAX® Pd
Powder 15, an iron therapy convenient for children. FeraMAX® Pd is
made with a homogeneous polysaccharide, Polydextrose, linked to
ferric (Fe3+) elemental iron to form the proprietary Polydextrose
Iron Complex (PDIC). This unique and patented formulation is the
foundation of future product innovations in oral iron
supplementation for BioSyent.
The Introduction of FeraMAX® Pd Maintenance 45
advances the legacy of FeraMAX®, which has made it the #1
recommended iron supplement brand by Canadian physicians and
pharmacists for seven consecutive years, including 2022 (Pharmacy
Practice+ and Profession Santé 2022 / The Medical Post and
Profession Santé 2022 – Survey on OTC Counselling and
Recommendations). BioSyent thanks healthcare providers and patients
who have trusted FeraMAX® for their iron health for more than a
decade.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty, and international business units.
As of the date of this press release, the
Company has 12,097,861 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
___________________i Friedman AJ, Chen Z, Ford P, Johnson CA,
Lopez AM, Shander A, Waters JH, van Wyck D. Iron deficiency anemia
in women across the life span. Journal of Women's Health (Larchmt).
2012 Dec;21(12):1282-9. doi: 10.1089/jwh.2012.3713. PMID:
23210492.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a5b0c69-2d30-4f86-b0f5-4b4ba3c52724
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024